Fig. 1 · Structure

Documents & Downloads

Bardoxolone methyl (RTA 402)

Cat. No. A11323 CAS 218600-53-4

IκB/IKK inhibitor

Bardoxolone methyl is an orally-available first-in-class synthetic triterpenoid. It is an inducer of the Nrf2 pathway, which can suppress oxidative stress and inflammation.

In Stock

Publications for Bardoxolone methyl

5 publications citing this product

  1. May Barakat, .et al. , Sci Rep, 2024, Oct 24;14(1):25258 PMID: 39448644
  2. Nakamura S, .et al. , Invest Ophthalmol Vis Sci, 2019, 60: 1943-1952 PMID: 31050722
  3. Hisamichi M, .et al. , Hypertens Res, 2018, Jan;41(1):8-17 PMID: 28978980
  4. Takahiko Imai, .et al. , Neurobiol Dis, 2016, May;89:136-46 PMID: 26850917
  5. Takagi T, .et al. , Free Radic Biol Med, 2014, 72:124-33 PMID: 24746614

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Bardoxolone methyl (CDDO-Me) activates NRF2-associated signaling with a strong dependence on KEAP1 C151 under the tested low-nanomolar conditions. Wild-type fibroblasts showed NQO1 induction, whereas C151S fibroblasts did not; responses to alternative inducers persisted in mutant cells. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
IKK (Cell-free assay)

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 0.36 μM Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 31051401]
A549 IC50 0.52 μM Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay [PMID: 31725288]
A549 IC50 0.63 μM Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay [PMID: 35238566]
A549 IC50 2.074 μM Antiproliferative activity against human A549 cells after 72 hrs by MTT assay [PMID: 29501947]
A549/TR IC50 1.703 μM Antiproliferative activity against human A549/TR cells after 72 hrs by MTT assay [PMID: 29501947]
B16-F10 IC50 5.85 μM Cytotoxicity against mouse B16F10 cells after 48 hrs by MTT assay [PMID: 24685545]
CCD-841CoN IC50 0.316 μM Antiproliferative activity against human CCD-841-CoN cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay [PMID: 25675144]
H9c2 IC50 5.2 μM Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability after 24 hrs by MTT assay [PMID: 28994286]
HCT-116 IC50 0.25 nM Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay [PMID: 30429953]
HCT-116 IC50 0.84 μM Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay [PMID: 35238566]
HCT-8 IC50 0.29 μM Antiproliferative activity against human HCT8 cells after 72 hrs by SRB assay [PMID: 30429953]
HCT-8 IC50 0.363 μM Antiproliferative activity against 5-FU resistant human HCT8 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay [PMID: 25675144]
HCT-8 IC50 0.399 μM Antiproliferative activity against human HCT8 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay [PMID: 25675144]
HEK293 IC50 2.2 μM Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 24 hrs by MTT assay [PMID: 28994286]
HepG2 IC50 0.26 μM Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay [PMID: 31051401]
HepG2 IC50 0.52 μM Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay [PMID: 31725288]
HepG2 IC50 4.99 μM Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay [PMID: 24685545]
HOS IC50 0.66 μM Antiproliferative activity against human HOS cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay [PMID: 31725288]
HT-29 IC50 0.28 μM Antiproliferative activity against human HT-29 cells after 72 hrs by SRB assay [PMID: 30429953]
HT-29 EC50 4.34 μM Anti-necroptotic activity in human HT-29 cells assessed as inhibition of TNFalpha/SM-164/Z-VAD-fmk (TSZ)-induced necroptosis by measuring increase in cell viability measured after 12 hrs by celltiter-glo luminescent cell viability assay [PMID: 33248849]

20 records · Scroll to view more

Bardoxolone methyl (RTA 402) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Bardoxolone methyl (RTA 402) from 2 published references. In vitro models include stable male wild-type and Keap1-C151S murine embryonic fibroblasts.

Bardoxolone methyl (RTA 402) In Vitro Studies

In HaCaT keratinocytes, 250 nM CDDO-Me produced a broader transcriptional response than 10 µM PRL-295 after 14 h. In a separate migration assay with proliferation suppressed, CDDO-Me impaired gap closure relative to vehicle. These findings limit generalizations about selectivity or wound repair across models. [2]

KEAP1 C151 dependence of NQO1 induction in fibroblasts

Cell-based study · Stable male wild-type and Keap1-C151S murine embryonic fibroblasts [1]

CDDO-Me increased Nqo1 transcript and NQO1 activity in wild-type MEFs, with no induction in C151S MEFs under the tested conditions. Alternative inducers retained activity in mutant cells; basal NQO1 differed between genotypes.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Nqo1 mRNA relative to genotype-matched vehiclerelative mRNA At 30 nM: WT 5.7-fold; C151S 1.3-fold (means labeled in Fig. 1B). WT induction at 3, 10 and 30 nM marked P < 0.05; no C151S induction marked.[1]
NQO1 enzymatic activity relative to genotype-matched vehiclerelative enzyme activity At 30 nM: WT 2.6-fold; C151S 0.9-fold (means labeled in Fig. 1G). WT induction marked P < 0.05.[1]

Literature-Reported Treatment Conditions

Treatment concentration
1, 3, 10 and 30 nM for qPCR; 1 and 30 nM for enzyme activity
Exposure duration
24 h for qPCR; 48 h for enzyme activity
Method
Cell treatment followed by beta-actin-normalized qPCR or protein-normalized lysate NQO1 activity assay
Vehicle
DMSO control; final DMSO fraction not specified in the selected methods
Co-treatment
No combined drug treatment. Separate 15Δ-PGJ2 (10 µM) and CdCl2 (30 µM) controls tested residual mutant responsiveness.
Reported limits
No EC50 or IC50 established. Three independent experiments per assay; numerical SD values not tabulated in the selected evidence.
Methods and source locations

Compound reported in the paper: Bardoxolone methyl; Compound label in the paper: CDDO-Me

Applies to the paper-reported methyl ester and stated model/conditions; no salt conversion, stereochemical re-analysis, or catalog lot validation.

Fig. 1B-G and caption; Results: CDDO-Me Induces Gene Expression and Enzyme Activity of NQO1; Materials, Cell Culture, RNA Preparations from Cells, NQO1 Enzyme Activity

Nqo1 mRNA relative to genotype-matched vehicle: qPCR normalized to beta-actin; genotype-specific vehicle set to 1; n = 3 independent experiments, mean ± SD; one-way ANOVA — Fig. 1B caption and labels; RNA Preparations from Cells

NQO1 enzymatic activity relative to genotype-matched vehicle: Protein-normalized lysate activity; vehicle set to 1 within genotype; n = 3 independent experiments, mean ± SD; ANOVA followed by Dunnett test — Fig. 1G and caption; NQO1 Enzyme Activity

CDDO-Me impaired keratinocyte gap closure under migration-assay conditions

Cell-based study · Human immortalized HaCaT keratinocytes; silicone-mold gap assay with mitomycin-C pretreatment to suppress proliferation [2]

At 250 nM, CDDO-Me impaired gap closure compared with 1% DMSO vehicle over the reported 72 h assay, increasing residual gap area and integrated wound burden. This is an in-vitro migration result, not an animal wound-healing result.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Residual gap area and total normalized gap-area AUCgap area / AUC Greater residual gap area and integrated wound burden with CDDO-Me than DMSO. Fig. 4C marks the CDDO-Me-versus-DMSO comparison *** (q ≤ 0.001).[2]

Literature-Reported Treatment Conditions

Treatment concentration
250 nM CDDO-Me
Exposure duration
0–72 h, imaged every 24 h
Method
Silicone-mold gap closure; ImageJ gap-area analysis after mitomycin-C pretreatment
Vehicle
1% DMSO in medium; treatment solutions adjusted to equal DMSO content
Co-treatment
Mitomycin-C pretreatment (1 µg/mL for 1 h), followed by washing before CDDO-Me; separate ADJ-310 and PRL-295 comparator groups at 10 µM.
Reported limits
No exact gap-area means or AUC values are inferred from bars. Culture methods list DMEM or DermaLife K for migration without assigning one to the plotted experiment.
Methods and source locations

Compound reported in the paper: Bardoxolone methyl; Compound label in the paper: CDDO-Me

Applies to the paper-reported methyl ester and stated model/conditions; no salt conversion, stereochemical re-analysis, or catalog lot validation.

Fig. 4B-E and caption; Results Sec3 migration paragraph; Methods Cell migration, HaCaT cell culture, Preparation of treatment solutions, Image analysis and Statistical analysis

Residual gap area and total normalized gap-area AUC: n = 8; mean ± SD; ImageJ; one-way ANOVA for AUC with Benjamini, Krieger and Yekutieli FDR correction. Time-course and time-point panels are from the same experiment. — Fig. 4B-D and caption; Cell migration; Statistical analysis

Broader keratinocyte transcriptional response to CDDO-Me than PRL-295

Cell-based study · HaCaT human keratinocytes; DMSO control, 250 nM CDDO-Me and 10 µM PRL-295 groups [2]

CDDO-Me increased expression of NRF2-associated genes while producing more differentially expressed genes than PRL-295 at the tested, unequal concentrations. The comparison does not establish direct binding to additional targets or NRF2 independence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Genes differentially expressed versus DMSODEG count CDDO-Me: 2,422; PRL-295: 1,373; shared DEGs: 616. NRF2-associated HMOX1 and GCLC appear among increased genes.[2]

Literature-Reported Treatment Conditions

Treatment concentration
250 nM CDDO-Me; separate 10 µM PRL-295 comparator
Exposure duration
14 h
Method
RNA sequencing using Illumina NovaSeq 6000; differential expression versus DMSO
Vehicle
DMSO in medium; shared preparation methods specify equalized 1% DMSO
Reported limits
No matched-exposure or equipotent comparison; no NRF2-null arm in this experiment. Pathway-enrichment graphics are not adopted.
Methods and source locations

Compound reported in the paper: Bardoxolone methyl; Compound label in the paper: CDDO-Me

Applies to the paper-reported methyl ester and stated model/conditions; no salt conversion, stereochemical re-analysis, or catalog lot validation.

Fig. 6A-E (first original figure image), caption; Results Sec5 first three paragraphs; Methods mRNA sequencing and Preparation of treatment solutions

Genes differentially expressed versus DMSO: n = 3 per group; DESeq2 adjusted P < 0.05 using Benjamini-Hochberg FDR correction; counts checked in Fig. 6C-D, gene labels in Fig. 6E — Fig. 6C-E; Sec5; mRNA sequencing methods

Bardoxolone methyl (RTA 402) In Vivo Studies

Oral CDDO-Me at 30 µmol/kg increased hepatic NQO1 activity in wild-type mice after one or three doses, but induction was absent in KEAP1-C151S mice. This supports C151-dependent signaling in mouse liver under the tested regimen. [1]

KEAP1 C151 dependence of hepatic NQO1 induction

Animal study · Male 7–10-week-old wild-type and homozygous Keap1-C151S mice on an albino C57BL/6J background [1]

Oral CDDO-Me increased hepatic NQO1 activity after one or three doses in wild-type mice; induction was absent in C151S mice. This is a pharmacodynamic signaling experiment, without a disease efficacy endpoint.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Hepatic NQO1 activity relative to genotype-matched vehiclerelative enzyme activity WT: 2.0-fold after one dose and 5.1-fold after three doses (Results); both P < 0.05. No induction in C151S mice.[1]

Conditions shared by the study groups

Route
Oral
Frequency
Single administration or every other day for three total doses
Treatment course
Liver activity measured 24 h after the last dose
Vehicle
10% DMSO, 10% Cremophor-EL and PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Wild-type
30 µmol/kg body weight per dose
Genotype-matched vehicle groupNQO1 activity increased 2.0-fold after one dose and 5.1-fold after three doses versus WT vehicle.[1]
KEAP1 C151S
30 µmol/kg body weight per dose
Genotype-matched vehicle groupNo induction of NQO1 activity relative to C151S vehicle.[1]
Wild-type
Model: Male 7–10-week-old wild-type and homozygous Keap1-C151S mice on an albino C57BL/6J background
Reported limits: Caption gives n = 3–5; exact per-arm n not assigned here.
KEAP1 C151S
Model: Male homozygous Keap1-C151S mice, same background and age range
Reported limits: Caption gives n = 3–5; exact per-arm n not assigned here.
Methods and source locations

Compound reported in the paper: Bardoxolone methyl; Compound label in the paper: CDDO-Me

Applies to the paper-reported methyl ester and stated model/conditions; no salt conversion, stereochemical re-analysis, or catalog lot validation.

Fig. 3B and caption; Results: C151 of KEAP1 is Required for CDDO-Me-Induced Stimulation of NRF2 Signaling in Vivo; Mice, Mouse Treatment with the NRF2 Inducers, NQO1 Enzyme Activity

Hepatic NQO1 activity relative to genotype-matched vehicle: NQO1 activity; vehicle set to 1; n = 3–5; mean ± SD; one-way ANOVA. Genotypes were not directly compared statistically. — Fig. 3B and caption; hepatic signaling Results

Wild-type · Fig. 3B and caption; Results: C151 of KEAP1 is Required for CDDO-Me-Induced Stimulation of NRF2 Signaling in Vivo; Mice, Mouse Treatment with the NRF2 Inducers, NQO1 Enzyme Activity

KEAP1 C151S · Fig. 3B and caption; Results: C151 of KEAP1 is Required for CDDO-Me-Induced Stimulation of NRF2 Signaling in Vivo; Mice, Mouse Treatment with the NRF2 Inducers, NQO1 Enzyme Activity

Specifications

Manufacturer Adooq Bioscience
Actions Inducer
CAS Number 218600-53-4
Applications IκB/IKK inhibitor
Formula C32H43NO4
Molecular Weight 505.7
Synonyms NSC 713200; CDDO-methyl ester; RTA 402
SMILES
C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)C(=O)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 21 mg/mL (41.52 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
2.3 mg/mL
Vehicle
4%DMSO+30% PEG300+5% Tween+61%ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Bardoxolone methyl (RTA 402) Research References

  1. [1] Gatbonton-Schwager T, Yagishita Y, Joshi T, et al. A Point Mutation at C151 of Keap1 of Mice Abrogates NRF2 Signaling, Cytoprotection in Vitro, and Hepatoprotection in Vivo by Bardoxolone Methyl (CDDO-Me) Molecular pharmacology (2023). PMID: 37188495 DOI: 10.1124/molpharm.123.000671 Source material
  2. [2] Barakat M, Han C, Chen L, et al. Non-electrophilic NRF2 activators promote wound healing in human keratinocytes and diabetic mice and demonstrate selective downstream gene targeting Scientific reports (2024). PMID: 39448644 DOI: 10.1038/s41598-024-75786-3 Source material

Publications

5 publications citing this product

  1. May Barakat, .et al. , Sci Rep, 2024, Oct 24;14(1):25258 PMID: 39448644
  2. Nakamura S, .et al. , Invest Ophthalmol Vis Sci, 2019, 60: 1943-1952 PMID: 31050722
  3. Hisamichi M, .et al. , Hypertens Res, 2018, Jan;41(1):8-17 PMID: 28978980
  4. Takahiko Imai, .et al. , Neurobiol Dis, 2016, May;89:136-46 PMID: 26850917
  5. Takagi T, .et al. , Free Radic Biol Med, 2014, 72:124-33 PMID: 24746614

Added to your cart

View Cart Checkout
Loading...